Akoya Biosciences, Inc. and Quanterix Corporation announced a definitive merger agreement on January 10, 2025, under which Quanterix will acquire Akoya in an all-stock transaction. This merger aims to create an integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.
Under the terms of the agreement, Akoya shareholders will receive 0.318 shares of Quanterix common stock for each share of Akoya common stock owned. This exchange ratio represented a 19% premium to Akoya’s unaffected stock price on November 14, 2024, the last full trading day prior to Akoya’s announcement of its review of strategic alternatives.
Following the close of the transaction, Quanterix shareholders are expected to own approximately 70% of the combined company, with Akoya shareholders owning approximately 30% on a fully diluted basis. The transaction is anticipated to generate approximately $40 million of annual cost synergies by the end of 2026 and is expected to close in the second quarter of 2025, subject to shareholder and regulatory approvals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.